Frontispiece

Free Access

Frontispiece: Sugar–Protein Connectivity Impacts on the Immunogenicity of Site-Selective Salmonella O-Antigen Glycoconjugate Vaccines

Giuseppe Stefanetti,

Giuseppe Stefanetti

Sclavo Behring Vaccines Institute For Global Health S.r.l., A GSK Company, Via Fiorentina 1, 53100 Siena (Italy)

Search for more papers by this author

Qi-Ying Hu,

Corresponding Author

Qi-Ying Hu

[email protected]

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Qi-Ying Hu, Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Francesca Micoli, Sclavo Behring Vaccines Institute For Global Health S.r.l., A GSK Company, Via Fiorentina 1, 53100 Siena (Italy)

Search for more papers by this author

Aimee Usera,

Aimee Usera

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Zack Robinson,

Zack Robinson

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Martin Allan,

Martin Allan

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Alok Singh,

Alok Singh

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Hidetomo Imase,

Hidetomo Imase

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Jennifer Cobb,

Jennifer Cobb

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Huili Zhai,

Huili Zhai

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Douglas Quinn,

Douglas Quinn

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Ming Lei,

Ming Lei

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Allan Saul,

Allan Saul

Sclavo Behring Vaccines Institute For Global Health S.r.l., A GSK Company, Via Fiorentina 1, 53100 Siena (Italy)

Search for more papers by this author

Roberto Adamo,

Roberto Adamo

GSK, Via Fiorentina 1, 53100 Siena (Italy)

Search for more papers by this author

Calman A. MacLennan,

Calman A. MacLennan

Jenner Institute, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ (UK)

Search for more papers by this author

Francesca Micoli,

Corresponding Author

Francesca Micoli

[email protected]

Sclavo Behring Vaccines Institute For Global Health S.r.l., A GSK Company, Via Fiorentina 1, 53100 Siena (Italy)

Qi-Ying Hu, Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Francesca Micoli, Sclavo Behring Vaccines Institute For Global Health S.r.l., A GSK Company, Via Fiorentina 1, 53100 Siena (Italy)

Search for more papers by this author

Giuseppe Stefanetti,

Giuseppe Stefanetti

Sclavo Behring Vaccines Institute For Global Health S.r.l., A GSK Company, Via Fiorentina 1, 53100 Siena (Italy)

Search for more papers by this author

Qi-Ying Hu,

Corresponding Author

Qi-Ying Hu

[email protected]

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Qi-Ying Hu, Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Francesca Micoli, Sclavo Behring Vaccines Institute For Global Health S.r.l., A GSK Company, Via Fiorentina 1, 53100 Siena (Italy)

Search for more papers by this author

Aimee Usera,

Aimee Usera

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Zack Robinson,

Zack Robinson

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Martin Allan,

Martin Allan

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Alok Singh,

Alok Singh

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Hidetomo Imase,

Hidetomo Imase

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Jennifer Cobb,

Jennifer Cobb

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Huili Zhai,

Huili Zhai

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Douglas Quinn,

Douglas Quinn

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Ming Lei,

Ming Lei

Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Search for more papers by this author

Allan Saul,

Allan Saul

Sclavo Behring Vaccines Institute For Global Health S.r.l., A GSK Company, Via Fiorentina 1, 53100 Siena (Italy)

Search for more papers by this author

Roberto Adamo,

Roberto Adamo

GSK, Via Fiorentina 1, 53100 Siena (Italy)

Search for more papers by this author

Calman A. MacLennan,

Calman A. MacLennan

Jenner Institute, Nuffield Department of Medicine, University of Oxford, Old Road Campus Research Building, Roosevelt Drive, Oxford, OX3 7DQ (UK)

Search for more papers by this author

Francesca Micoli,

Corresponding Author

Francesca Micoli

[email protected]

Sclavo Behring Vaccines Institute For Global Health S.r.l., A GSK Company, Via Fiorentina 1, 53100 Siena (Italy)

Qi-Ying Hu, Novartis Institutes for BioMedical Research, 100 Technology Square, Cambridge, MA 02139 (USA)

Francesca Micoli, Sclavo Behring Vaccines Institute For Global Health S.r.l., A GSK Company, Via Fiorentina 1, 53100 Siena (Italy)

Search for more papers by this author

First published: 26 October 2015

https://doi.org/10.1002/anie.201584561

Share a link

Email
Wechat
Bluesky

Graphical Abstract

Glycoproteins In their Communication on page 13198 ff., Q.-Y. Hu, F. Micoli et al. present two methods for the preparation of glycoconjugate vaccines with one single sugar chain linked to one or two positions of a carrier protein.

Volume54, Issue45

November 2, 2015

Frontispiece: Sugar–Protein Connectivity Impacts on the Immunogenicity of Site-Selective Salmonella O-Antigen Glycoconjugate Vaccines

Graphical Abstract

Figures

Information

About Wiley Online Library

Help & Support

Opportunities

Connect with Wiley

Frontispiece: Sugar–Protein Connectivity Impacts on the Immunogenicity of Site-Selective Salmonella O-Antigen Glycoconjugate Vaccines

Graphical Abstract

Figures

Related

Information